US Patent Issued to Jiangsu Hengrui Medicine, SHANGHAI HENGRUI PHARMACEUTICAL on Sept. 30 for "Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,428,482, issued on Sept. 30, was assigned to Jiangsu Hengrui Medicine Co. Ltd. (Lianyungang, China) and SHANGHAI HENGRUI PHARMACEUTICAL Co. LTD. (Shanghai).

"Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof" was invented by Xiaoling Gu (Shanghai), Xin Ye (Shanghai), Hu Ge (Shanghai) and Weikang Tao (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are an anti-PD-1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. Specifically, provided are a humanized anti-PD-1 antibody containing a specific CDR region and an antigen-binding fragment thereof, a pharmaceutical composition ...